Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 297

1.

Effects of recombinant human granulocyte colony-stimulating factor (filgrastim) on ECG parameters in neutropenic patients: a single-centre, prospective study.

Guneysel O, Onur OE, Denizbasi A.

Clin Drug Investig. 2009;29(8):551-5. doi: 10.2165/00044011-200929080-00005.

PMID:
19591516
2.

Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy.

Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Heisrath-Evans J, Koczyk-Scripka K, Pashko S, Norgard MJ, Barnes HM, Taylor WR, Thompson KA, Smith LF, Ueno WM, Dobrzynski RF, Warren RD, Katcher D, Byrne PJ, Dunning DM, Winokur SH, Lockey JL, Cambareri RJ, Butler TP, Meister RJ, Fiegert JM.

Support Care Cancer. 1997 Jul;5(4):289-98.

PMID:
9257425
3.
4.

A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.

Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, Windsor K, Gore I, Cantrell J, Thompson KA, Taylor WR, Barnes HM, Schiff SA, Shields JA, Cambareri RJ, Butler TP, Meister RJ, Feigert JM, Norgard MJ, Moraes MA, Helvie WW, Patton GA, Mundy LJ, Henry D, Sheridan MJ, et al.

Cancer Invest. 1998;16(6):366-73.

PMID:
9679526
5.

Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients.

Gruson D, Hilbert G, Vargas F, Valentino R, Chene G, Boiron JM, Reiffers J, Gbikpi-Benissan G, Cardinaud JP.

Crit Care Med. 2000 Sep;28(9):3155-60.

PMID:
11008974
6.

A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia.

Hartmann P, Lammertink J, Mansmann G, Hübel K, Salzberger B, Stützer H, Engert A, Fätkenheuer G.

Eur J Med Res. 2005 Jan 28;10(1):29-35.

PMID:
15737951
8.

Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.

Shochat E, Rom-Kedar V.

Clin Cancer Res. 2008 Oct 15;14(20):6354-63. doi: 10.1158/1078-0432.CCR-08-0807.

9.

Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.

Rivera E, Erder MH, Moore TD, Shiftan TL, Knight CA, Fridman M, Brannan C, Danel-Moore L, Hortobagyi GN; Risk Model Study Group.

Cancer. 2003 Jul 15;98(2):222-8.

10.

Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia.

deBoisblanc BP, Mason CM, Andresen J, Logan E, Bear MB, Johnson S, Shellito J, Summer WR, Nelson S.

Respir Med. 1997 Aug;91(7):387-94.

11.

Granulocytic growth factors and cancer-related neutropenia: limited effects.

[No authors listed]

Prescrire Int. 2006 Oct;15(85):189-91.

PMID:
17128529
12.

Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.

Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu ML, Hirsch J, Mahoney A, Carrell J, Boyd E, Grzegorzewski KJ.

Pharm Res. 2002 Nov;19(11):1720-9.

PMID:
12458679
13.

Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.

Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G.

Oncology. 2009;77(2):107-12. doi: 10.1159/000229504. Epub 2009 Jul 21.

PMID:
19622901
14.

Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor.

Cottle TE, Fier CJ, Donadieu J, Kinsey SE.

Semin Hematol. 2002 Apr;39(2):134-40. Review.

PMID:
11957197
15.

[Filgrastim therapy in acute nonlymphoblastic leukemia].

Grudeva-Popova Zh, Karnolski I.

Ter Arkh. 2000;72(12):58-9. Russian.

PMID:
11201836
16.

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.

Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G.

Clin Ther. 2009 May;31(5):1069-81. doi: 10.1016/j.clinthera.2009.05.019.

PMID:
19539108
17.

Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.

André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC, Bernard JL.

Anticancer Drugs. 2007 Mar;18(3):277-81.

PMID:
17264759
18.

Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.

Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.

Pharmacoeconomics. 2007;25(4):343-51.

PMID:
17402806
19.

Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?

Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG.

Ann Pharmacother. 2006 Mar;40(3):402-7. Epub 2006 Feb 21.

PMID:
16492793
20.

Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis.

Wickramanayake PD, Scheid C, Josting A, Katay I, Schulz A, Diehl V.

Eur J Med Res. 1995 Dec 18;1(3):153-6.

PMID:
9445760

Supplemental Content

Support Center